DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
+8.61%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$3.13B
AUM Growth
+$3.13B
(-6.5%)
Cap. Flow
-$950M
Cap. Flow
% of AUM
-30.34%
Top 10 Holdings %
Top 10 Hldgs %
41.39%
Holding
77
New
10
Increased
20
Reduced
24
Closed
8
Top Buys
| 1 |
MBX
MBX Biosciences, Inc. Common Stock
MBX
|
$78.4M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$54.8M |
| 3 |
Immunovant
IMVT
|
$41.7M |
| 4 |
Guardant Health
GH
|
$34.4M |
| 5 |
Kura Oncology
KURA
|
$30.8M |
Top Sells
| 1 |
CYBN
Cybin
CYBN
|
$503M |
| 2 |
Amgen
AMGN
|
$180M |
| 3 |
Insmed
INSM
|
$134M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$122M |
| 5 |
Travere Therapeutics
TVTX
|
$95.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
argenx
ARGX
$43.6B
| $198M | 6.28% | 365,000 -35,000 | -9% | -$19M |
|
2
Dynavax Technologies
DVAX
$1.19B
| $140M | 4.43% | 12,526,486 +1,626,486 | +15% | +$18.1M |
|
|
3
Guardant Health
GH
$8.41B
| $138M | 4.37% | 6,000,560 +1,500,560 | +33% | +$34.4M |
|
|
4
Apellis Pharmaceuticals
APLS
$3.48B
| $127M | 4.03% | 4,400,654 +1,900,654 | +76% | +$54.8M |
|
|
5
Immunovant
IMVT
$2.56B
| $124M | 3.93% | 4,347,464 +1,463,728 | +51% | +$41.7M |
|
|
SWTX
6
DELISTED
SpringWorks Therapeutics
SWTX
| $123M | 3.91% | 3,843,900 +143,900 | +4% | +$4.61M |
|
7
Dyne Therapeutics
DYN
$1.92B
| $118M | 3.74% | 3,282,000 -718,000 | -18% | -$25.8M |
|
|
ITCI
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $117M | 3.72% | 1,600,693 +62,771 | +4% | +$4.59M |
|
9
Ocular Therapeutix
OCUL
$2.12B
| $111M | 3.51% | 12,721,460 | – | – |
|
10
Intellia Therapeutics
NTLA
$1.22B
| $102M | 3.23% | 4,950,000 +150,000 | +3% | +$3.08M |
|
11
Alkermes
ALKS
$4.78B
| $98M | 3.11% | 3,500,000 | – | – |
|
|
VRNA
12
Verona Pharma
VRNA
$9.16B
| $91.5M | 2.9% | 3,180,025 -819,975 | -20% | -$23.6M |
|
13
Ionis Pharmaceuticals
IONS
$6.8B
| $88.1M | 2.8% | 2,200,000 +200,000 | +10% | +$8.01M |
|
14
Nurix Therapeutics
NRIX
$714M
| $86.9M | 2.76% | 3,868,104 -123,396 | -3% | -$2.77M |
|
15
Viridian Therapeutics
VRDN
$1.5B
| $85.3M | 2.71% | 3,750,945 -172,904 | -4% | -$3.93M |
|
|
BCYC
16
Bicycle Therapeutics
BCYC
$511M
| $80.3M | 2.55% | 3,548,001 +57,495 | +2% | +$1.3M |
|
|
MBX
17
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $78.4M | 2.49% | +3,018,935 | New | +$78.4M |
|
18
Axsome Therapeutics
AXSM
$6.05B
| $77M | 2.44% | 857,219 -995,565 | -54% | -$89.5M |
|
19
Pliant Therapeutics
PLRX
$101M
| $66.9M | 2.12% | 5,972,257 | – | – |
|
20
Apogee Therapeutics
APGE
$2.17B
| $58.7M | 1.86% | 1,000,000 | – | – |
|
|
AUTL
21
Autolus Therapeutics
AUTL
$399M
| $55.4M | 1.76% | 15,272,172 | – | – |
|
22
Structure Therapeutics
GPCR
$1.11B
| $53.6M | 1.7% | 1,220,508 +270,508 | +28% | +$11.9M |
|
23
Olema Pharmaceuticals
OLMA
$375M
| $47.8M | 1.51% | 4,000,000 | – | – |
|
24
Terns Pharmaceuticals
TERN
$609M
| $46.5M | 1.48% | 5,576,558 -523,442 | -9% | -$4.37M |
|
25
4D Molecular Therapeutics
FDMT
$288M
| $44.3M | 1.4% | 4,096,452 +35,051 | +0.9% | +$379K |
|